Puma Biotechnology, Inc. (PBYI) Posts Q2 Loss of $1.05/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts PBYI Hot Sheet
Join SI Premium – FREE
Puma Biotechnology, Inc. (NYSE: PBYI) reported Q2 EPS of ($1.05), $0.39 worse than the analyst estimate of ($0.66).
For earnings history and earnings-related data on Puma Biotechnology, Inc. (PBYI) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Phoenix Education Partners (PXED) PT Lowered to $32 at Jefferies
- Netflix gains after Ackman endorsement and AI feature launch
- Walmart stock climbs on AI shopping tool expansion
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
